Physician profile
Gopa Rahman
NPI 1962503433
$12,473.42
in general payments reported to CMS, 2019-2025
33 companies · $2,292 in 2025
The $2,292 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,323 · 2020: $815 · 2021: $2,380 · 2022: $986 · 2023: $2,168 · 2024: $1,509 · 2025: $2,292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,969.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $4,408.33 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $1,342.56 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,275.51 | 2019-2025 | Ofev, Jardiance |
| Novo Nordisk INC | $982.74 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $700.14 | 2019-2025 | Otezla, Repatha, Tezspire |
| Glaxosmithkline, LLC. | $613.63 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Abbvie INC. | $467.98 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $439.75 | 2019-2025 | |
| Esperion Therapeutics, INC. | $349.95 | 2020-2024 | Nexletol |
| Pfizer INC. | $333.07 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $244.73 | 2023-2024 | Uzedy |
| E.R. Squibb & Sons, L.L.C. | $182.62 | 2019-2023 | Eliquis |
| Lilly USA, LLC | $177.68 | 2019-2025 | Jardiance, Kisunla |
| Horizon Therapeutics Plc | $164.84 | 2023 | Krystexxa |
| Kowa Pharmaceuticals America, INC. | $133.67 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $124.18 | 2019 | |
| Amarin Pharma, INC. | $60.13 | 2019 | |
| Neurocrine Biosciences, INC. | $58.73 | 2024 | Ingrezza |
| Merck Sharp & Dohme LLC | $44.85 | 2019 | |
| Boston Scientific Corporation | $43.61 | 2019-2025 | Watchman Flx |
| Endo Pharmaceuticals INC. | $42.60 | 2019 | |
| Novartis Pharmaceuticals Corporation | $37.51 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $36.30 | 2019 | |
| Medtronic, INC. | $31.68 | 2021-2022 | |
| Dermira, INC. | $30.30 | 2020 | |
| Alnylam Pharmaceuticals INC. | $29.12 | 2022 | |
| Exact Sciences Corporation | $23.51 | 2024 | Cologuard Collection Kit |
| Seqirus USA INC | $18.38 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.54 | 2021 | |
| Gilead Sciences, INC. | $16.94 | 2019 | |
| Impulse Dynamics (USA) INC. | $16.14 | 2023 | Optimizer |
| Arbor Pharmaceuticals, INC. | $13.17 | 2019 | |
| Medtronic USA, INC. | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gopa Rahman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.